GSK's Arexvy RSV Vaccine Recommended for All Adults by European Regulators

GlaxoSmithKline plc (LSE:GSK) received a nod from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending its respiratory syncytial virus (RSV) vaccine, Arexvy, for use in adults aged 18 and up. This marks a significant broadening from the vaccine's existing approval for older adults and at-risk populations.

Previously cleared for adults over 60, and those between 50 and 59 with elevated health risks, Arexvy's approval extension would potentially give all European adults access to RSV protection pending the European Commission's final decision slated for February 2026. The regulatory move mirrors a growing acknowledgement of RSV's impact beyond just the elderly.

RSV is no stranger to causing disruption - it annually affects roughly 64 million people worldwide, with the European Union seeing about 158,000 hospitalizations among adults every year. Hospital stays related to RSV in adults often come with heightened risks for severe complications and higher mortality, underscoring the need for preventive measures. Notably, the real burden may be underestimated, partly because routine testing for RSV among adults is not standard practice.

Arexvy has already secured authorization in over 65 countries for adults 60+ and in more than 55 nations for those 50-59 at increased risk, including major markets such as the US, Japan, and Europe. GSK continues to push for broader vaccine indications in other regions, emphasizing the product's global reach potential.

Sanjay Gurunathan, head of GSK's Vaccines and Infectious Diseases R&D, framed the positive CHMP opinion as a step forward in enlarging prevention options against serious RSV disease. Expanding vaccine eligibility could reshape RSV prevention strategies across adult demographics within Europe.

The broader approval of Arexvy could mean that a greater swathe of the adult population gains access to vaccination, a jump from targeting primarily seniors and high-risk groups. This development comes amid increasing awareness of respiratory viruses' burden beyond pediatric and geriatric cohorts.

With the decision expected early next year, all eyes will be on how European regulators finalize this expansion, which may influence other markets where GSK is seeking similar authorizations. Should regulatory wheels turn as anticipated, vaccine availability could notably expand starting 2026.

The question remains whether this approval will also accelerate adoption rates and lead to wider public health impacts in curbing RSV's adult hospitalizations or if uptake will be tempered by factors such as vaccine hesitancy or cost reimbursement frameworks across EU countries.